{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:55:48Z","timestamp":1770566148009,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1031982"],"award-info":[{"award-number":["APP1031982"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmacogenomics Research for Individualised Medicine"},{"DOI":"10.13039\/100013121","name":"Sydney West Translational Cancer Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1031982"],"award-info":[{"award-number":["APP1031982"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmacogenomics Research for Individualised Medicine"},{"DOI":"10.13039\/100013121","name":"Sydney West Translational Cancer Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.breast.2019.05.009","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T16:31:32Z","timestamp":1557333092000},"page":"52-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?"],"prefix":"10.1016","volume":"46","author":[{"given":"Clara I.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bavanthi","family":"Balakrishnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary L.","family":"Balleine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Provan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Liddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Wilcken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2019.05.009_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","article-title":"Tamoxifen, hot flashes and recurrence in breast cancer","volume":"108","author":"Mortimer","year":"2008","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2019.05.009_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11096-013-9833-5","article-title":"Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer","volume":"36","author":"Ayres","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.breast.2019.05.009_bib3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","article-title":"Clinical and biomarker predictors of side effects from tamoxifen","volume":"132","author":"Lorizio","year":"2012","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2019.05.009_bib4","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","article-title":"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes","volume":"23","author":"Goetz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2019.05.009_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","article-title":"Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial","volume":"9","author":"Cuzick","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2019.05.009_bib6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/1471-2407-13-612","article-title":"Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites","volume":"13","author":"Jager","year":"2013","journal-title":"BMC Canc"},{"key":"10.1016\/j.breast.2019.05.009_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/bjc.2012.278","article-title":"Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial","volume":"107","author":"Sestak","year":"2012","journal-title":"Br J Canc"},{"key":"10.1016\/j.breast.2019.05.009_bib8","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1200\/JCO.2010.31.4427","article-title":"Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study","volume":"29","author":"Irvin","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2019.05.009_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jnci\/djs125","article-title":"CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial","volume":"104","author":"Regan","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2019.05.009_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-014-2963-1","article-title":"Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22","volume":"145","author":"Baxter","year":"2014","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2019.05.009_bib11","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-15-1470","article-title":"Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring-the TADE study","volume":"22","author":"Fox","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2019.05.009_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.breast.2019.05.009_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/tpj.2014.34","article-title":"Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer","volume":"15","author":"Saladores","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.breast.2019.05.009_bib14","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1158\/1078-0432.CCR-17-3028","article-title":"Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial","volume":"24","author":"Neven","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2019.05.009_bib15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.18.00307","article-title":"Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study","volume":"37","author":"Sanchez-Spitman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2019.05.009_bib16","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","article-title":"Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence","volume":"34","author":"Chirgwin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2019.05.009_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-016-3765-4","article-title":"Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions","volume":"156","author":"Johns","year":"2016","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2019.05.009_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/gme.0b013e3181679150","article-title":"Mayo clinic and north central cancer treatment group hot flash studies: a 20-year experience","volume":"15","author":"Loprinzi","year":"2008","journal-title":"Menopause"},{"key":"10.1016\/j.breast.2019.05.009_bib19","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2011.37.5865","article-title":"Nonestrogenic management of hot flashes","volume":"29","author":"Loprinzi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2019.05.009_bib20","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","article-title":"Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Boekhout","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2019.05.009_bib21","article-title":"A\u00a0randomized placebo-controlled phase III trial of low-dose tamoxifen for the prevention of recurrence in women with operated hormone-sensitive breast ductal or lobular carcinoma in situ","volume":"79","author":"DeCensi","year":"2019","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"10.1016\/j.breast.2019.05.009_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","author":"DeCensi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2019.05.009_bib23","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1200\/JCO.2001.19.23.4280","article-title":"Methodologic lessons learned from hot flash studies","volume":"19","author":"Sloan","year":"2001","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761930503X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761930503X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:41:08Z","timestamp":1760776868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097761930503X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":23,"alternative-id":["S096097761930503X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2019.05.009","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2019.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}